Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression - Major Depressive Disorder
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized, double-blind, sham-controlled pilot study will evaluate the feasibility, acceptability, safety, and preliminary clinical effects of transcranial alternating current stimulation as an adjunctive treatment for adolescents with major depressive disorder. It will also examine changes in depressive symptoms and related clinical outcomes, while exploring potential effects on emotional regulation, cognitive function, and brain function following the intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: tACS — This intervention uses the NEXALIN ADI alternating current stimulation device from Beijing Naisilin Technology Co., Ltd., to deliver targeted stimulation to the prefrontal cortex and bilateral mastoid regions. The prefrontal cortex electrode directly stimulates the cerebral cortex, while the mastoid electrodes ensure the synchronized activation of bilateral neural pathways. Stimulation is applied at a frequency of 77.5 Hz and a current intensity of 15 mA, aiming to optimize brainwave synchronization and modulate brain activity. Participants will undergo daily sessions lasting approximately 40 minutes each, for a total of 20 sessions over 4 weeks. The non-invasive nature of the intervention, combined with its precise targeting of specific brain regions, distinguishes it from other neuromodulation therapies. The treatment aims to enhance neural synchronization, promote neuroplasticity, and provide a non-pharmacological therapeutic alternative for patients.
  • Device: tACS — In the sham stimulation group, participants will receive intervention using a sham device that is identical in appearance, operation, and stimulation protocol to the real tACS device, but does not deliver any current. Both participants and operators will be unable to distinguish between real and sham stimulation based on the device's appearance, sound, or tactile feedback. Device allocation will follow a randomized code generated in advance to ensure blinding and proper group assignment.

Primary Outcomes

  • Recruitment Feasibility (Number of Participants Enrolled) (From the start of recruitment to completion of enrollment, up to 2 years)
  • Intervention adherence (number of participants who completed the full 20 treatment sessions) (End of treatment at Week 4)
  • Retention Rate (Number of Participants Remaining at 16-Week Follow-up) (From randomization through the final follow-up assessment at Week 16)
  • Response rate and remission rate of depressive symptoms (Baseline, throughout the 4-week treatment period, and during follow-up through Week 16)
  • Incidence of Adverse Events and Serious Adverse Events (From the first stimulation session through the final follow-up assessment at Week 16)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2027-10-01
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Chongqing Medical University
Contact Information
Study Contact:
Xinyu Zhou
15823996993
zhouxinyu@cqmu.edu.cn
Xinyu Zhou
15823996993
zhouxinyu@cqmu.edu.cn
The First Affiliated Hospital of Chongqing Medical University
Interventions
  • Device: tACS — This intervention uses the NEXALIN ADI alternating current stimulation device from Beijing Naisilin Technology Co., Ltd., to deliver targeted stimulation to the prefrontal cortex and bilateral mastoid regions. The prefrontal cortex electrode directly stimulates the cerebral cortex, while the mastoid electrodes ensure the synchronized activation of bilateral neural pathways. Stimulation is applied at a frequency of 77.5 Hz and a current intensity of 15 mA, aiming to optimize brainwave synchronization and modulate brain activity. Participants will undergo daily sessions lasting approximately 40 minutes each, for a total of 20 sessions over 4 weeks. The non-invasive nature of the intervention, combined with its precise targeting of specific brain regions, distinguishes it from other neuromodulation therapies. The treatment aims to enhance neural synchronization, promote neuroplasticity, and provide a non-pharmacological therapeutic alternative for patients.
  • Device: tACS — In the sham stimulation group, participants will receive intervention using a sham device that is identical in appearance, operation, and stimulation protocol to the real tACS device, but does not deliver any current. Both participants and operators will be unable to distinguish between real and sham stimulation based on the device's appearance, sound, or tactile feedback. Device allocation will follow a randomized code generated in advance to ensure blinding and proper group assignment.
Study Locations (1 sites)
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality 40000 China
Eligibility Criteria
Inclusion Criteria: 1. Age 12-18 years. 2. Meet DSM-5 diagnostic criteria for a current depressive episode, as confirmed by the K-SADS-PL. 3. Children's Depression Rating Scale-Revised (CDRS-R) score ≥40 at baseline. 4. Stable psychotropic medication treatment for at least 4 weeks prior to enrollment and willingness to continue the same regimen throughout the study. Exclusion Criteria: 1. Psychiatric comorbidities other than anxiety disorders. 2. Depression with psychotic features. 3. Young Mania Rating Scale (YMRS) score \>13. 4. History of neurological disorders (e.g., epilepsy, traumatic brain injury) or severe physical illnesses (e.g., thyroid disease, lupus, diabetes, significant liver, kidney, or lung impairment, major trauma). 5. Previous treatment with electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), tACS, or other neurostimulation therapies. 6. Current use of antiepileptic drugs or high-dose benzodiazepines. 7. History of alcohol or substance abuse or dependence. 8. Pregnant or breastfeeding females. 9. Contraindications to MRI. 10. Current high suicide risk.
Conditions Chronic Kidney Disease (Stages 4 and 5),...
Phase NA
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Physiologic Insulin Resensitization (PIR) — PIR is a physician-directed treatment that uses an exterior infusion pump to deliver insulin intravenously.

Primary Outcomes

  • Estimated Glomular Filtration Rate (eGFR) (12 and 24 weeks)
  • Blood Urea Nitrogen/Creatinine Ratio (BUN/Cr) (12 and 24 weeks)
  • Cystatin C (12 and 24 weeks)
  • Urine albumin-creatinine ratio (ACR) (12 and 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-14
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Well Cell Global
Principal Investigators:
  • Sungchun Lee, MD (PRINCIPAL_INVESTIGATOR) - Arizona Kidney Disease and Hypertension Centers
Contact Information
Study Contact:
Richard Marchase, PhD
205-612-4763
rmarchase@gmail.com
Samantha Villaverde
904-806-8280
samantha@wellcellglobal.com
Cynthia Carrizoza, MS, CCRP
602-997-0484
ccarrizoza@akdhc.com
Arizona Kidney Disease and Hypertension Center
Interventions
  • Other: Physiologic Insulin Resensitization (PIR) — PIR is a physician-directed treatment that uses an exterior infusion pump to deliver insulin intravenously.
Study Locations (2 sites)
Arizona Kidney Disease and Hypertension Center, Phoenix, Arizona 85027 United States
Innovative Diabetic Center, Scottsdale, Arizona 85258 United States
Eligibility Criteria
Inclusion Criteria: * Is age 18 or older (male or female) * Have a documented diagnosis of CKD stage 3b, 4, or 5 and T2DM of 6 months or greater prior to screening. Patients may have treatment regimens associated with T2DM that include diabetic oral and/or injectable medications including insulin and/or GLP-1 receptor agonists. * In the opinion of the Investigator, has been on an appropriate, stable regimen for management of any complications present for the past six (6) months. * In the opinion of the Investigator, is able to do all of the following: * Provide valid informed consent. * Understand and comply with study procedures as presented in the consent process. * Has the capacity or support to attend all required visits. * If female, the subject must meet either of the following sets of conditions: o Is of non-childbearing potential, defined as meeting either of the following criteria: * Age ≥50 years and post-menopausal for at least one (1) year * Surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy * Is of childbearing potential and meets both of the following criteria: * Has a negative serum pregnancy test (beta-human chorionic gonadotropin) at screening. * Agrees to practice an acceptable method of birth control (contraception) from screening until at least 30 days after last study treatment Exclusion Criteria: * Has in the past two (2) years received treatment for a malignancy. * Current pregnancy or intends to become pregnant during the study * Has in the past one (1) year used non-prescription opioids or psychoactive drugs. * Has in the past six (6) months had a hypoglycemic event requiring urgent care and/or administration of glucagon, osteocalcin, or parenteral glucose, unless approved for enrollment by the Medical Monitor. * Has within the past one (1) month participated in a clinical study involving either of the following: * An investigational drug or procedure for any clinical indication * An investigation method for glucose control using approved agents * Is nursing or is planning to nurse during the study. * Has at screening a positive test for HIV (4th gen. screen), HBsAg, or HCV viral load. * Has at screening, one or more of the following abnormal lab results: * Hb \<8 g/dL * WBC \<2,000/µL * Platelets \<50,000/µL * ALT, AST, or Alkaline Phosphatase \>5x ULN * ALT or AST \>2.5x ULN, and Total Bilirubin \>2x ULN * Serum albumin \<3 g/dL * Has - in the opinion of the Investigator - psychiatric, behavioral, cognitive and/or clinical dysfunction (whether or not related to known medical illness or drug / alcohol use) that would affect the subject's safety and/or compliance. * Is on active dialysis at time of screening
Conditions Chronic Kidney Disease in Type 2 Diabete...
Phase Not Applicable
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Obesity is considered a global pandemic and is associated with various diseases and metabolic complications, such as type 2 diabetes mellitus, high blood pressure, cholesterol disorders, cancer, cardiovascular disease, and kidney disease. Obesity can affect the kidneys in two main ways: indirectly, through mechanisms related to diabetes mellitus and/or high blood pressure, and directly, through complex proteins called "adipokines," which are produced by adipocytes. Many of these adipokines are secreted by adipocytes under normal conditions, as they contribute to maintaining immune defenses and energy production. However, in obesity these adipokines acquire harmful properties and produce chronic inflammation in vital organs, such as the heart, blood vessels, the pancreas, and the kidney, leading to a deterioration in liver and kidney function. New drugs such as glucagon-like peptide-1 receptor agonists (GLP-1Ras / Semaglutide), are not only effective to regulate blood sugar levels, but they produce weight loss improving kidney and liver function. However, little is known about their specific effect on the adipose tissue. Therefore, studies focusing on how these drugs work in fat could help us understand how diseased adipose tissue can affect patients with heart, liver, and kidney disease. Investigators are asking patients who attend the diabetes clinics associated with the University of Alberta to join the study.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Primary Outcomes

  • Correlation between kidney disease progression and cardiometabolic changes (From enrollment to the end of follow-up at 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-23
Completion: 2028-01-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alberta
Collaborators: Novo Nordisk A/S
Principal Investigators:
  • Paolo Raggi, M.D (PRINCIPAL_INVESTIGATOR) - University of Alberta
  • Luis G D'Marco, M.D; Ph,D. (PRINCIPAL_INVESTIGATOR) - CEU Cardenal Herrera University
Contact Information
Study Contact:
Maryam Rezaeifar, M.D
rezaeif1@ualberta.ca
Mazankowski Alberta Heart Institute
Luis G D'Marco, M.D; Ph.D.
dmarcoga@ualberta.ca
Mazankowski Alberta Heart Institute
Interventions
N/A
Study Locations (1 sites)
Mazankowski Alberta Heart Institute, Edmonton, Alberta T6G 2B7 Canada
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years of age. * Patients diagnosed with T2DM (\>18 months) and CKD in stages G1, G2, G3a, G3b and G4; the CKD staging will be established according to the eGFR as per the KDIGO guidelines (G1: eGFR ≥90 ml/min/1.73m2; G2: 60-89 ml/min/1.73m2; G3a: 45-59 ml/min/1.73m2; G3b: 30-44 ml/ min/1.73m2; G4: 15-29 ml/ min/1.73m2). * Patients with T2DM and CKD, with or without semaglutide treatment. * Patients who voluntarily agree to participate and sign informed consent. Exclusion Criteria: * Patients \<18 years of age. * Pregnant, breastfeeding, or an intention of becoming pregnant or not using adequate contraceptive measures (including country-specific adequate measures, if any) * Patients diagnosed with T2DM and CKD in stage G5 or stage G4 requiring dialysis as per KDIGO guidelines. * Previous participation in this trial (screened or randomized) * Patients diagnosed with neuropsychiatric diseases that prevent them from understanding the benefits/risks associated with the project or voluntarily choosing to participate. * Known or suspected allergy to trial medication(s), excipients, or related products * Contraindications to study medication(s), worded specifically as stated in the Product Monograph * Refusal to participate or consent revocation.
Conditions Depression, Anxiety, Stress
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research is being done to find out the effectiveness, feasibility, and acceptability of a college student-delivered cognitive-behavioral therapy (CBT) intervention in high schools in rural Schuylkill County, Pennsylvania to treat mental health problems (i.e. depression and anxiety) in adolescents. This project will respond to the need for evidence-based, acceptable, accessible, and low-cost adolescent cognitive-behavioral interventions that lead to long-term improvements in adolescents' mental health outcomes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Student Delivered Cognitive Behavioral Therapy Intervention — Our study aims to evaluate whether a 12-week cognitive-behavioral therapy (CBT) program delivered in both group and individual formats by trained college students can effectively help adolescents with symptoms of depression, anxiety, and stress. We will assess the program's feasibility, acceptability, and effectiveness in a high school setting. Sessions will cover topics such as: understanding connections between thoughts, feelings, and behaviors, identifying and challenging unhelpful thought patterns, using exposure principles to face feared situations, building problem-solving skills, and engaging in positive activities.

Primary Outcomes

  • Patient-Reported Outcomes Measurement Information System (PROMIS) 8-item Emotional Distress-Depression (Baseline, Week 6, Week 12)
  • PROMIS 8-item Emotional Distress-Anxiety (Baseline, Week 6, Week 12)
  • PROMIS 8-item Psychological Stress Experiences (Baseline, Week 6, Week 12)
  • Recruitment Rate (Through study completion, an average of 2 years)
  • Retention Rate (Through study completion, an average of 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-25
Completion: 2027-06-30
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Milton S. Hershey Medical Center
Contact Information
Study Contact:
Jamal H Essayli, PhD
(717) 531-0003
jessayli@pennstatehealth.psu.edu
Jamal H Essayli, PhD
717-531-0003
jessayli@pennstatehealth.psu.edu
Penn State College of Medicine
Interventions
  • Behavioral: Student Delivered Cognitive Behavioral Therapy Intervention — Our study aims to evaluate whether a 12-week cognitive-behavioral therapy (CBT) program delivered in both group and individual formats by trained college students can effectively help adolescents with symptoms of depression, anxiety, and stress. We will assess the program's feasibility, acceptability, and effectiveness in a high school setting. Sessions will cover topics such as: understanding connections between thoughts, feelings, and behaviors, identifying and challenging unhelpful thought patterns, using exposure principles to face feared situations, building problem-solving skills, and engaging in positive activities.
Study Locations (1 sites)
Penn State College of Medicine, Hershey, Pennsylvania 17033 United States
Eligibility Criteria
Inclusion Criteria: * High school students ages 13-18 years. * Attending a participating rural high school in Schuylkill County, Pennsylvania. * Presenting with self-reported symptoms of depression, anxiety, or stress. Must have a t-score ≥ 55 on one or more of the following three measures: i. PROMIS Emotional Distress Depression short-form questionnaire ii. PROMIS Emotional Distress Anxiety short-form questionnaire iii. PROMIS Psychological Stress Experiences short-form questionnaire * English-speaking (to ensure comprehension of CBT materials and assessments). Exclusion Criteria: * Diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, or seizure disorder. * Assessed to be at high risk for suicide or requiring immediate crisis intervention. * Inability to participate in school-based sessions due to scheduling conflicts or behavioral concerns.
Conditions Aerobic Exercise, Early Stage Triple Neg...
Phase NA
Enrollment 33
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To learn if participating in a supervised exercise program can help participants with early-stage TNBC who are receiving ICI therapy before undergoing breast surgery.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Exercise — Cardiorespiratory training via treadmill walking for 30 minutes; participants will be supervised by a trained exercise physiologist.

Primary Outcomes

  • Adherence (Approximately 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-23
Completion: 2030-10-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 33 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Jasmine Sukumar, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Salma Foster
713-794-1613
SYFoster@mdanderson.org
Livia Geoffrey
832-728-6175
LGeoffrey@mdanderson.org
Jasmine Sukumar, MD
713-264-1576
jsukumar@mdanderson.org
MD Anderson Cancer Center
Interventions
  • Other: Exercise — Cardiorespiratory training via treadmill walking for 30 minutes; participants will be supervised by a trained exercise physiologist.
Study Locations (1 sites)
MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria 1. female and male participants 18 years or older and willing to provide Informed Consent 2. clinical stage 2 or 3 TNBC (estrogen receptor and progesterone receptor ≤ 10% by immunohistochemistry (IHC) and human epidermal growth factor-2 (HER2) negative (IHC 0, IHC1+, or IHC 2+ with negative fluorescence in situ hybridization)) 3. Physically able to walk independently without assistive device and able to march in place for 30 seconds without assistive device 4. Eastern Co-Operative Oncology Group (ECOG) Performance Status 0-1 5. Planned receipt of neoadjuvant chemoICI therapy (carboplatin/taxane in combination with pembrolizumab; taxane options are weekly paclitaxel or every 3 week docetaxel) 6. clearance to participate in the study by the patient's medical oncologist 7. normal bone marrow function 8. able to read/complete study forms/assessments and understand instructions in English Exclusion criteria: a) Any physical condition which hinders the ability to safely participate in exercise including: uncontrolled or symptomatic cardiac/respiratory disease (e.g. uncontrolled angina, unusual shortness of breath, congestive heart failure, symptomatic peripheral vascular disease), stroke/myocardial infarction in the past year, fragility fracture, recent or planned orthopedic surgery, or any comorbid condition precluding exercise per the treating physician b) receipt of medications known to influence immune function including corticosteroids (\>10 mg prednisone equivalent), other immune-suppressive medication, or beta blockers47 c) Any infection or vaccination within the last 4 weeks d) e) Known HIV-positive participants on combination antiretroviral therapy f) concurrent participation in a therapeutic clinical trial or other exercise program g) pregnant h) medically advised to not exercise i) Unable to walk on a motor-driven treadmill for \~30 minutes at study enrollment j) Adults unable to consent k) No external catheters/drains (e.g., nephrostomy tube, foley catheter). A colostomy or Ileostomy is acceptable. l) Prior or concurrent non-breast malignancy. Those with prior cancers treated with curative intent are eligible. Participants with known (or history) of hepatitis B positive, or hepatitis C positive infection
Conditions Respiratory Complications, Opioid Induce...
Phase Not Applicable
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to determine if a relationship can be detected between the administration of an opioid and quantitative respiratory depression in spontaneously breathing non-intubated patients who have undergone general anesthesia and have received perioperative opioids. The primary aim is to determine the temporal effect of opioid administration on respiratory depression as assessed by minute ventilation with a reduction of at least 20% in the percent of predicted minute ventilation. A secondary aim is to determine a dose response of opioid administration and its effect on minute ventilation. The investigators aim to determine the influence of opioid administration on minute ventilation on spontaneously breathing patients during post-anesthesia care unit (PACU) stay.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Respiratory volume monitoring — Noninvasive continuous respiratory monitoring utilizing bio-impedance to detect tidal volumes, respiratory rate, and minute ventilation.

Primary Outcomes

  • Respiratory interventions 1 (Within 4 hours of patient admittance to Post Anesthetic Care Unit (PACU))
  • Respiratory interventions 2 (Within 4 hours of patient admittance to Post Anesthetic Care Unit)
  • Respiratory interventions 3 (Within 4 hours of patient admittance to Post Anesthetic Care Unit)
  • Respiratory interventions 4 (Within 4 hours of patient admittance to Post Anesthetic Care Unit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-01
Completion: 2029-02-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wayne State University
Principal Investigators:
  • Wael Saasouh, MD (PRINCIPAL_INVESTIGATOR) - Wayne State University
Contact Information
Study Contact:
George M McKelvey, PhD
3135986036
George.McKelvey@northstaranesthesia.com
George McKelvey M Clinical Co-ordinator, PhD
3135986036
George.McKelvey@northstaranesthesia.com
Detroit Medical Center
Interventions
  • Diagnostic Test: Respiratory volume monitoring — Noninvasive continuous respiratory monitoring utilizing bio-impedance to detect tidal volumes, respiratory rate, and minute ventilation.
Study Locations (1 sites)
Detroit Medical Center, Detroit, Michigan 48201 United States
Eligibility Criteria
Inclusion Criteria: * Written informed consent * Adults ≥18 years of age and ≤85 years of age * Patients planned for general anesthesia with an expected anesthetic time of at least 2 hours * Patients expected to receive postoperative opioid analgesia Exclusion Criteria: * Non-operative procedure (imaging) * Patients not admitted to the PACU postoperatively * Use of patient-controlled analgesia systems * Female patients who are pregnant or breastfeeding * Patients with asymmetric lung disease * American Society of Anesthesiologists (ASA) classification V * Emergency surgery (ASA E Modifier)
Conditions Prediabetes / Type 2 Diabetes
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, single-blind, controlled, parallel clinical trial to examine the efficacy and safety of AMPK Charge+® with and without use of semaglutide on glycemic response in adults with prediabetes or Type 2 Diabetes. The main question it aims to answer is: What is the difference in change in fasting blood glucose and insulin, and hemoglobin A1c (HbA1c) from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide? Participants will consume AMPK Charge+® with or without semaglutide injections and will be evaluated for glycemic response parameters.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Dietary Supplement: AMPK Charge+® — Participants will be instructed to consume 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1.
  • Dietary Supplement: AMPK Charge+® with semaglutide — Participants will be instructed to use the provided measuring tool to take 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1. Participants will be instructed to administer subcutaneous semaglutide once per week beginning with a dose of 0.25 mg for four weeks at which point participants will be instructed to increase the dose to 0.5 mg per week for the remainder of the study period.

Primary Outcomes

  • The difference in change in fasting blood glucose between AMPK Charge+® and AMPK Charge+® with semaglutide (Day 0 to 84)
  • The difference in change in fasting insulin between AMPK Charge+® and AMPK Charge+® with semaglutide (Day 0 to 84)
  • The difference in change in hemoglobin A1c (HbA1c) between AMPK Charge+® and AMPK Charge+® with semaglutide (Day 0 to 84)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-05
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: QuickSilver Scientific
Collaborators: KGK Science Inc.
Principal Investigators:
  • David Crowley, MD (PRINCIPAL_INVESTIGATOR) - KGK Science Inc.
Contact Information
Study Contact:
Marc Moulin, PhD
2267819094
mmoulin@kgkscience.com
Marc Moulin, PhD
+12267819094;ext=300
mmoulin@kgkscience.com
KGK Science Inc.
bhallam@kgkscience.com
KGK Science Inc.
Interventions
  • Dietary Supplement: AMPK Charge+® — Participants will be instructed to consume 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1.
  • Dietary Supplement: AMPK Charge+® with semaglutide — Participants will be instructed to use the provided measuring tool to take 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1. Participants will be instructed to administer subcutaneous semaglutide once per week beginning with a dose of 0.25 mg for four weeks at which point participants will be instructed to increase the dose to 0.5 mg per week for the remainder of the study period.
Study Locations (1 sites)
KGK Science Inc., London, Ontario N6B3L1 Canada
Eligibility Criteria
Inclusion Criteria: 1. Males \& females between 18 years of age or older 2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or, Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) * Double-barrier method * Intrauterine devices * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s) * Vasectomy of partner at least 6 months prior to screening * Abstinence and agrees to use contraception if becomes sexually active during this study 3. Individuals eligible for, but not currently taking, semaglutide therapy as per standard-of-care including adults with: 1. Prediabetes (HbA1c 6.0-6.5%) who are treatment naïve 2. Type 2 Diabetes (HbA1c 6.5-7.5%) who are treatment naïve and metformin is inappropriate due to contraindication or intolerance 4. Self-reported stable body weight defined as not having gained or lost more than 5 kg of body weight in the three months prior to baseline 5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, sleep, use of nicotine, tobacco and cannabinoid products) as much as possible throughout the study 6. Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits 7. Provided voluntary, written, informed consent to participate in the study Exclusion Criteria: 1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study 2. Allergy, sensitivity, intolerance, or dietary restriction preventing use of study products 3. Personal or family history of MTC or in patients with MEN 2 4. Unstable metabolic disease or chronic diseases as assessed by the QI 5. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI 6. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3) 7. Type I diabetes or diabetic ketoacidosis 8. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis 9. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months 10. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI 11. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI 12. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable 13. Individuals with an autoimmune disease or are immune compromised 14. Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI 15. Self-reported confirmation of blood/bleeding disorders as assessed by the QI 16. Alcohol intake average of \>2 standard drinks per day as assessed by the QI 17. Alcohol or drug abuse within the last 12 months 18. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the study products (See Section 7.3) 19. Clinically significant abnormal laboratory results at screening as assessed by the QI 20. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit 21. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI 22. Individuals who are unable to give informed consent 23. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Conditions Adolescent, Major Depressive Disorder (M...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This cohort study involves the dynamic collection of clinical information from adolescent patients with major depressive episodes (including both major depressive disorder and bipolar disorder), encompassing serum parameters, physiological-behavioral signals, neuroimaging data, and neuropsychological scales. The study aims to summarize the comprehensive clinical characteristics of this population, identify new risk factors, and establish multivariate predictive models for treatment response, cognitive and emotional impairments. Furthermore, this research will thoroughly investigate the underlying neural mechanisms linking clinical manifestations and neuroimaging features in major depressive episodes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: data collection and follow-up — Main measures and data collection methods: 1. Recording of baseline demographic and clinical information of the participants. 2. Multimodal magnetic resonance imaging. 3. Heart rate variability. 4. Electroencephalography. 5. Emotion-related questionnaires. 6. Cognitive tests. 7. Behavioral data collection using wearable devices. 8. Blood samples collection.

Primary Outcomes

  • The 17-item Hamilton Depression Rating Scale (HAMD-17) (at baseline, week 1, week 2, week 4, week 24, and up to 1 year)
  • Change in brain functional connectivity measured by resting-state functional MRI (at baseline, week 1, week 2, week 4, week 24, and up to 1 year)
  • Change in Heart Rate Variability (HRV) via wearable device (Within 4 weeks, but not exceeding 1 year.)
  • Change in daily step count and activity patterns recorded via wearable device (Within 4 weeks, but not exceeding 1 year.)
  • Change in Cytokines (reported in pg/mL) (at baseline, week 1, week 2, week 4, week 24, and up to 1 year)
  • Change in Composite Immune-Inflammatory Ratio Index (unitless) (at baseline, week 1, week 2, week 4, week 24, and up to 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-01
Completion: 2029-03
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu Province Nanjing Brain Hospital
Principal Investigators:
  • Fei Wang (STUDY_CHAIR) - the Affiliated Nanjing Brain Hospital, Nanjing Medical University
Contact Information
Study Contact:
Zexin Lin
86-13906900678
zexinlin@stu.njmu.edu.cn
Jia Duan
86-025-83295957
jia_duan@yeah.net
Fei Wang
86-025-83295957
fei.wang@yale.edu
210000
Interventions
  • Other: data collection and follow-up — Main measures and data collection methods: 1. Recording of baseline demographic and clinical information of the participants. 2. Multimodal magnetic resonance imaging. 3. Heart rate variability. 4. Electroencephalography. 5. Emotion-related questionnaires. 6. Cognitive tests. 7. Behavioral data collection using wearable devices. 8. Blood samples collection.
Study Locations (1 sites)
210000, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: * Between 10 and 20 years of age; * Diagnosis of major depressive disorder (MDD) or bipolar disorder (BD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Diagnosis is assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) for participants aged ≥18 years, or the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL) for participants aged \<18 years; * Current moderate to severe depressive episode, defined as Hamilton Depression Rating Scale (HAMD) score ≥17; * Participants and 1 or 2 parents (patients' age\< 18 years old) provide informed consent after the detailed description of the study. Exclusion Criteria: * Prior treatment with repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), electroconvulsive therapy (ECT), or standard psychological therapy within 6 months prior to screening; * Comorbidity with other DSM-IV Axis I disorders or personality disorders; * Judged clinically to be at serious risk of suicide; * Diabetes mellitus, hypertension, vascular and infectious diseases and other major medical comorbidities; * Unstable medical conditions, e.g., severe asthma; Neurological disorders, e.g., history of head injury with loss of consciousness for ≥ five minutes, cerebrovascular diseases, brain tumors and neurodegenerative diseases; * Mental retardation or autism spectrum disorder; * Contraindications to MRI (e.g., severe claustrophobia, pacemakers, metal implants); * Current drug or alcohol abuse or dependence; * Pregnant or lactating females.
Conditions Breast Cancer, Brain Metastases From Bre...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this real-world study (RWS) is to evaluate the effectiveness of Trop-2 ADC (sacituzumab govitecan) in treating breast cancer patients with brain metastases, and to understand the safety profile of this drug in real clinical practice across multiple centers. The main questions it aims to answer are: Does Trop-2 ADC (sacituzumab govitecan) improve intracranial outcomes in breast cancer patients with brain metastases (e.g., intracranial objective response rate, intracranial progression-free survival)? What types and rates of adverse events do breast cancer patients with brain metastases experience when receiving Trop-2 ADC (sacituzumab govitecan)? This is a multicenter real-world study, which will collect and analyze data from breast cancer patients with brain metastases who have received Trop-2 ADC (sacituzumab govitecan) in routine clinical care (no randomization or placebo control, consistent with real-world clinical scenarios). Participants (breast cancer patients with brain metastases who received Trop-2 ADC) will have their data collected from: Electronic health records (EHRs) across multiple medical centers Regular clinical follow-up visits (e.g., once every 4-8 weeks) for imaging assessments (to evaluate brain metastasis changes) and safety monitoring Medical records documenting treatment responses, disease progression, and any adverse events during treatment and follow-up

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Drug: Sacituzumab Govitecan (SG) — Sacituzumab Govitecan

Primary Outcomes

  • Real world progression free survival (rwPFS) (up to 48 months from the initiation of the study treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University Cancer Hospital & Institute
Contact Information
Study Contact:
Guohong Song, Doctor of Medicine (M.D.)
0086-88121122-2066
songguohong918@hotmail.com
Guohong Song, Doctor of Medicine (M.D.)
881211222066
songguohong918@hotmail.com
Beijing Cancer Hospital
songguohong918@hotmail.com
Beijing Cancer Hospital
Interventions
  • Drug: Sacituzumab Govitecan (SG) — Sacituzumab Govitecan
Study Locations (1 sites)
Beijing Cancer Hospital, Beijing, Beijing Municipality 100142 China
Eligibility Criteria
Inclusion Criteria: * At least 18 years old (based on actual age at the time of signing the informed consent form), with no restriction on gender * Able to understand the study purpose, risks, and benefits, and voluntarily sign the written informed consent form; if the patient has cognitive impairment or is unable to express themselves independently, their legal guardian/authorized agent shall sign after being fully informed, and provide valid authorization documents. * Have access to complete medical records (including breast cancer primary lesion diagnosis data, brain metastasis diagnosis data, SG treatment records, follow-up data, etc.) in the study collaborating medical institutions/specified medical systems to ensure traceability of treatment processes and outcomes. Diagnosed with breast cancer via histopathological/cytopathological examination, with the diagnostic report issued by a tertiary hospital or the study-designated pathology center. * Diagnosed with breast cancer brain metastasis based on meeting any of the following conditions: ① Definitive diagnosis by a physician with associate senior title or above, combining contrast-enhanced cranial magnetic resonance imaging (MRI)/computed tomography (CT) with clinical symptoms and signs; ② Postoperative pathology of brain metastatic lesions confirming breast cancer metastasis; ③ Pathological examination of brain metastatic lesion biopsy specimens confirming breast cancer metastasis. * No restrictions on the number, size of brain metastatic lesions, presence of meningeal metastasis, or presence of brain metastasis-related symptoms (e.g., headache, limb dysfunction). * Previous treatment with Sacituzumab Govitecan (SG), with clear medication records (prescription orders, medical orders, pharmacy dispensing records, etc.), and no restrictions on the line of SG treatment, dosage, or treatment cycles (both completion of full-cycle treatment and early discontinuation due to adverse reactions/progression are acceptable). * No restriction on the start time of SG treatment ; patients currently receiving SG treatment, who have completed SG treatment, or who have discontinued SG treatment due to objective reasons are all eligible. * Stable vital signs at present, without the following uncontrolled severe conditions: ① Severe infections such as sepsis and severe pneumonia (symptoms relieved and laboratory indicators normalized after anti-infective treatment); ② Epileptic seizures within the past 3 months (or uncontrolled without standardized anti-epileptic treatment); ③ Failure of major organs such as heart, liver, and kidney (e.g., New York Heart Association (NYHA) Class Ⅳ cardiac function, Child-Pugh Class C liver function, chronic kidney disease Stage 5) . * The patient/guardian can cooperate with study follow-up (outpatient follow-up, telephone follow-up, electronic medical record extraction, etc.), and survival status, disease progression, subsequent treatment, adverse reactions, and other information can be obtained within the expected follow-up period. Exclusion Criteria: * Complicated with other primary malignant tumors (excluding breast cancer), and the tumor was in an active stage within the past 5 years (not achieving complete remission or disease-free survival for more than 5 years). * Unable to cooperate with informed consent or follow-up due to mental illness, cognitive impairment, etc., and without qualified guardian assistance. * Concurrent participation in other interventional clinical trials (e.g., randomized controlled trials), which may affect data collection and result interpretation of this study. * Other conditions judged by the researcher to affect study quality or patient safety .
Conditions Type 2 Diabetes Mellitus (T2DM), Health-...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This prospective cross-sectional observational study aims to explore the relationships among psychological well-being, depression, and quality of life in patients with type 2 diabetes attending the outpatient metabolic clinic at National Taiwan University Hospital. The study will collect data using standardized instruments, including the EQ-5D Health-Related Quality of Life Questionnaire, the PHQ-9 Depression Scale, and the Shalom Scale of Psychological Well-Being, along with demographic and clinical variables such as age, sex, education, body mass index, HbA1c, disease duration, and psychosocial support indicators. Descriptive statistics, Pearson correlation analyses, ANOVA, and multiple linear regression modeling will be performed to identify factors associated with psychological well-being. The findings are expected to provide evidence-based insights to inform tailored interventions and improve the mental health and quality of life of patients with type 2 diabetes.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Primary Outcomes

  • Shalom Scale Total Score (Psychological Well-Being) (At enrollment (single outpatient visit; questionnaires completed in approximately 30-40 minutes).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-19
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Principal Investigators:
  • Ching-Yuan Wang (PRINCIPAL_INVESTIGATOR) - National Taiwan University Hospital, Department of Internal Medicine (Metabolism)
Contact Information
Study Contact:
YI-CHIEH CHUNG, MSN, RN
+886-2-2312-3456
ejchung@gmail.com
YI-CHIEH CHUNG, Registered Nurse
+886-2-2312-3456
ejchung@gmail.com
National Taiwan University Hospital - Metabolism
Interventions
N/A
Study Locations (1 sites)
National Taiwan University Hospital - Metabolism, Taipei, 100229 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18 years or older with full legal capacity. 2. Clinically diagnosed with Type 2 Diabetes Mellitus and receiving ongoing outpatient care. 3. Able to read and understand Chinese questionnaires and complete self-administered forms. 4. Understand the study purpose and procedures and provide written informed consent. Exclusion Criteria: 1. Presence of major psychiatric disorders (e.g., schizophrenia, bipolar disorder, major depressive disorder). 2. Moderate to severe cognitive impairment or dementia, as assessed by the clinical physician, making it impossible to complete the questionnaires. 3. Currently experiencing acute diabetic complications (e.g., diabetic ketoacidosis, hyperosmolar hyperglycemic state) or hospitalization. 4. Severe language or other communication barriers preventing expression of consent or understanding of study content.
Conditions Advanced ER+/HER2- Breast Cancer
Phase PHASE1, PHASE2
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multi-center, open label, phase Ib/II clinical trial aimed at evaluating the safety, preliminary efficacy characteristic and PK characteristics of QLS1304 in combined with endocrine therapy in ER+/HER2- breast cancer patients. This study was divided into two stages: combo dose escalation and dose expansion.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: QLS1304 tablet+Fulvestrant or QLC1401 — QLS1304 combined with endocrine therapy
  • Drug: QLS1304 tablet+Fulvestrant,AI or QLC1401+CDK4/6i — QLS1304 combined with endocrine therapy

Primary Outcomes

  • Recommended Phase II Dose (RP2D) of QLS1304 in combo therapy (through study completion,an average of 2 years)
  • objective response rate(ORR) (through study completion,an average of 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-01-16
Completion: 2031-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Qilu Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Jian Zhang
021-34778299
syner2000@163.com
Fudan University Cancer Hospital
Interventions
  • Drug: QLS1304 tablet+Fulvestrant or QLC1401 — QLS1304 combined with endocrine therapy
  • Drug: QLS1304 tablet+Fulvestrant,AI or QLC1401+CDK4/6i — QLS1304 combined with endocrine therapy
Study Locations (1 sites)
Fudan University Cancer Hospital, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Volunteer to participate in this study, sign an informed consent form and have good compliance; 2. Age ≥ 18 years old, Male or female 3. ECOG score: 0-1 4. Expected survival ≥ 12 weeks 5. Local recurrent or metastatic advanced ER+/HER2- breast cancer confirmed by histopathology or cytopathology; 6. Failed to at least one therapy line of endocrine therapy ; 7. Baseline presence of at least one measurable lesion according to the RECIST v1.1; 8. The functional level of important organs is basically normal, meeting the requirements of the scheme; 9. Female subjects with fertility and male subjects must agree to use highly effective contraception during the study treatment period and within 180 days after the last medication; 10. Female subjects with fertility must have a negative serum HCG test within 7 days before the first medication in the study, and must be in non lactation. 11. Volunteer to participate in this clinical trial, willing and able to follow the procedures related to clinical visits and research, understand the research procedures, and have signed informed consent. Exclusion Criteria: 1. Subjects have received live or attenuated live vaccines within 4 weeks before the first use of the investigational drug. 2. Subjects have undergone major organ surgery within 4 weeks before the first use of the investigational drug. 3. Subjects require long-term or high-dose use of non-steroidal drugs. 4. Subjects have not recovered from adverse events (AEs) caused by previous anti-tumor treatment to ≤ grade 1. 5. Subjects have a known or suspected severe allergy to the investigational drug or any of its components. 6. Subjects have other active malignant tumors within 3 years before the first use of the investigational drug. 7. Subjects have brain metastases and/or carcinomatous meningitis or leptomeningeal disease. 8. Subjects have active tuberculosis, radiation pneumonitis, drug-induced pneumonitis, pulmonary fibrosis, or other diseases, symptoms, or signs of severe lung function impairment. 9. Subjects are unable to swallow tablets or had gastrointestinal abnormalities that the investigator assessed as potentially affecting drug absorption. 10. Subjects have a history of severe cardiovascular or cerebrovascular disease within 6 months before the first use of the investigational drug. 11. Subjects have a hypertension medial history that blood is not well controlled despite treatment with multiple antihypertension drugs.
Conditions Pelvic Floor Disorder, Loneliness, Postp...
Phase NA
Enrollment 130
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Generative artificial intelligence (genAI) postpartum chatbot — Participants randomly assigned to the chatbot intervention will be provided a URL to a secure, HIPAA-compliant web application hosted by UC San Diego (https://knolohealth.org/). This application features a generative AI-powered chatbot designed to deliver postpartum pelvic floor education and support. The chatbot is available for a 4-week period following enrollment and can be accessed at any time during that window. The chatbot's educational content is grounded in reputable, evidence-based resources, including national and international urogynecology patient education materials, as well as postpartum recovery guidelines. Participants can interact with the chatbot to ask questions and will receive tailored educational responses related to pelvic floor health. No additional in-person study visits are required for the intervention. Chatbot usage data (e.g., frequency, timing and content of chatbot interactions) will be collected to assess engagement and user needs.
  • Other: Standard of Care (SOC) — Access to the same postpartum care that participants would receive if they did not participate in the study.

Primary Outcomes

  • Prolapse and incontinence knowledge (Will be administered to both groups at three time points: 1) at enrollment, 2) post-intervention or standard of care, 3) at 6 months postpartum.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-08
Completion: 2026-11-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Contact Information
Study Contact:
Alexandra C Nutaitis, DO
858-657-7344
anutaitis@health.ucsd.edu
Cecile Ferrando, MD, MPH
(858) 657-1238
cferrando@health.ucsd.edu
Cecile Ferrando, MD, MPH
University of California San Diego
Interventions
  • Other: Generative artificial intelligence (genAI) postpartum chatbot — Participants randomly assigned to the chatbot intervention will be provided a URL to a secure, HIPAA-compliant web application hosted by UC San Diego (https://knolohealth.org/). This application features a generative AI-powered chatbot designed to deliver postpartum pelvic floor education and support. The chatbot is available for a 4-week period following enrollment and can be accessed at any time during that window. The chatbot's educational content is grounded in reputable, evidence-based resources, including national and international urogynecology patient education materials, as well as postpartum recovery guidelines. Participants can interact with the chatbot to ask questions and will receive tailored educational responses related to pelvic floor health. No additional in-person study visits are required for the intervention. Chatbot usage data (e.g., frequency, timing and content of chatbot interactions) will be collected to assess engagement and user needs.
  • Other: Standard of Care (SOC) — Access to the same postpartum care that participants would receive if they did not participate in the study.
Study Locations (1 sites)
University of California San Diego, La Jolla, California 92093 United States
Eligibility Criteria
Inclusion Criteria: 1. Has the capacity to provide informed consent 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Postpartum persons, aged \>18 years old 4. Primiparous 5. Vaginal or cesarean delivery 6. English Speaking 7. Internet access and proficiency of internet access 8. Access to a smartphone 9. Postpartum 2-6 weeks Exclusion Criteria: 1. Multiparous 2. Major neonatal anomaly 3. Delivery \< 34 weeks gestational age 4. Intrauterine fetal demise (IUFD) 5. Enrollment in any interfering studies 6. Unanticipated NICU admission 7. Discharge home without live baby 8. Surrogates/gestational carrier 9. Birthing individuals with baby placed for adoption 10. Currently pregnant 11. Psychiatric history requiring psychiatric hospitalization prior to delivery 12. Other psychiatric conditions needing immediate attention and intervention as determined by study team and/or treatment team